Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RHEA-1: AZD9793 in Advanced or Metastatic Solid Tumours
NCT06795022Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2025
- Primary completion
- Jun 2027
- Modality
- Antibody Conjugates, Trispecific Antibodies, T-cell Engagers
- Countries
- 7
01
Overview
A Phase 2 trial of AZD9793 in hepatocellular carcinoma (HCC), sponsored by AstraZeneca. Started Mar 2025; status: recruiting.
02
Drugs
AZD9793
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06795022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06795022.